Adalta Capital Management LLC purchased a new position in Syros Pharmaceuticals Inc (NASDAQ:SYRS) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 11,380 shares of the company’s stock, valued at approximately $111,000.
A number of other institutional investors have also recently made changes to their positions in the stock. Nationwide Fund Advisors boosted its stake in Syros Pharmaceuticals by 249.8% in the 2nd quarter. Nationwide Fund Advisors now owns 7,024 shares of the company’s stock worth $113,000 after purchasing an additional 5,016 shares in the last quarter. Bank of New York Mellon Corp lifted its stake in Syros Pharmaceuticals by 17.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 35,329 shares of the company’s stock valued at $520,000 after acquiring an additional 5,305 shares during the period. New York State Common Retirement Fund lifted its stake in Syros Pharmaceuticals by 167.9% during the 2nd quarter. New York State Common Retirement Fund now owns 13,400 shares of the company’s stock valued at $216,000 after acquiring an additional 8,399 shares during the period. Russell Investments Group Ltd. bought a new position in Syros Pharmaceuticals during the 3rd quarter valued at about $133,000. Finally, Two Sigma Investments LP lifted its stake in Syros Pharmaceuticals by 80.3% during the 4th quarter. Two Sigma Investments LP now owns 21,197 shares of the company’s stock valued at $206,000 after acquiring an additional 9,439 shares during the period. Institutional investors own 48.18% of the company’s stock.
In other Syros Pharmaceuticals news, insider Jeremy P. Springhorn acquired 15,000 shares of the stock in a transaction dated Friday, December 15th. The shares were purchased at an average price of $9.08 per share, for a total transaction of $136,200.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Srinivas Akkaraju acquired 109,774 shares of the stock in a transaction dated Thursday, December 14th. The stock was acquired at an average price of $9.03 per share, for a total transaction of $991,259.22. The disclosure for this purchase can be found here. Insiders bought a total of 334,198 shares of company stock worth $3,127,458 in the last quarter. Company insiders own 33.60% of the company’s stock.
Several research firms have issued reports on SYRS. Zacks Investment Research cut shares of Syros Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, January 11th. HC Wainwright restated a “hold” rating and set a $10.00 target price on shares of Syros Pharmaceuticals in a research note on Thursday, December 21st. BidaskClub upgraded shares of Syros Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Oppenheimer set a $28.00 target price on shares of Syros Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, January 8th. Finally, Cowen restated a “buy” rating on shares of Syros Pharmaceuticals in a research note on Monday, December 11th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $22.36.
ILLEGAL ACTIVITY NOTICE: “11,380 Shares in Syros Pharmaceuticals Inc (SYRS) Purchased by Adalta Capital Management LLC” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3258628/11380-shares-in-syros-pharmaceuticals-inc-syrs-purchased-by-adalta-capital-management-llc.html.
Syros Pharmaceuticals Profile
Syros Pharmaceuticals, Inc is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines.
Want to see what other hedge funds are holding SYRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syros Pharmaceuticals Inc (NASDAQ:SYRS).
Receive News & Ratings for Syros Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syros Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.